Sofiva Genomics (6615) Stock Overview

Sofiva Genomics Co.,Ltd. provides genetic testing services in Taiwan and internationally. The company offers prenatal services, including thalassemia carrier screening; tests for microdeletion syndromes and single-gene abnormalities; detection of common chromosome abnormalities, selected microdeletions syndromes, and selected skeletal dysplasia genetic mutations; multiple genetic diseases detection; folate metabolism genetic screening; spinal muscular atrophy carrier screening; fragile X syndrome carrier screening; congenital infection screening; risk assessment for early/late-onset preeclampsia; maternal serum screening for down syndrome; and karyotyping. It also provides cancer services, such as cancer scans; real-time monitoring of tumor dynamics; hereditary cancer related genetic tests; and hereditary women's cancer tests for breast, colon, ovarian, and endometrial cancer, as well as human papillomavirus screening. In addition, the company offers rare diseases genetic testing services; and preimplantation genetic diagnosis and NGS-based preimplantation genetic screening services. Further, it provides new-born genetic testing services comprising baby scans; hereditary sensorineural hearing loss screening; congenital central hypoventilation syndrome screening; congenital cytomegalovirus infection screening test; and atopic dermatitis genetic screening. Additionally, the company offers biochemical and chromosome testing, as well as advisory and support services. It serves expectant parents, patients with genetic disorders, and their families. Sofiva Genomics Co.,Ltd. was founded in 2012 and is based in Taipei, Taiwan.